Type II Diabetes and its Treatment by Mountain, Gregory
Otterbein University 
Digital Commons @ Otterbein 
Nursing Student Class Projects (Formerly MSN) Student Research & Creative Work 
Summer 2015 
Type II Diabetes and its Treatment 
Gregory Mountain 
Otterbein University, gregory.mountain@otterbein.edu 
Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn 
 Part of the Endocrine System Diseases Commons, Medical Pathology Commons, and the Nursing 
Commons 
Recommended Citation 
Mountain, Gregory, "Type II Diabetes and its Treatment" (2015). Nursing Student Class Projects (Formerly 
MSN). 81. 
https://digitalcommons.otterbein.edu/stu_msn/81 
This Project is brought to you for free and open access by the Student Research & Creative Work at Digital 
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an 
authorized administrator of Digital Commons @ Otterbein. For more information, please contact 
digitalcommons07@otterbein.edu. 
Treatments 
Type II Diabetes and its Treatment 
Gregory Mountain RN, BSN,CCRN 
Signs and Symptoms. References Bussell, G. (2014). Providing Dietary Advice for People with 
Type 2 Diabetes. Journal of Community Nursing. 28(5). 
60-67. Retrieved from 
http://web.b.ebscohost.com/ehost/pdfviewer/pdfvie
wer?sid=7afc1861-3094-413c-8aad-
ae7ddb776ab8%40sessionmgr198&vid=4&hid=116  
Centers for Disease Control and Prevention. (1991). The 
Prevention and Treatment of Complications of Diabetes 
Mellitus A Guide for Primary Care Practitioners. Retrieved 
from 
http://wonder.cdc.gov/wonder/prevguid/p0000063/p000
0063.asp  
Eyadeh, A.A., & Jennings, P.E. (2015). Diabetes Evidence-
Based Management 77: New Pharmacological 
approaches to Diabetes Management. Practice Nursing. 
26(3). 140-146. Retrieved from 
http://web.a.ebscohost.com/ehost/search/advanced?s
id=f15070a0-ed65-4645-b218-
33475188a1bd%40sessionmgr4002&vid=0&hid=4201 
Jia-Haur Hu, B.R., Lin, C., Miller, B.R., Nuygen, H., & Nuygen, 
Q.T. (2014). New and Emerging Drugs and Targets for 
Type 2 Diabetes: Reviewing the Evidence. American 
Health & Drug Benefits, 7(8), 452-461. Retrieved from 
http://web.a.ebscohost.com/ehost/search/advanced?s
id=f15070a0-ed65-4645-b218-
33475188a1bd%40sessionmgr4002&vid=0&hid=4201 
Liu, C., &Wu, D. (2014). Efficacy and Safety of Dipeptidyl 
Peptidase-4 Inhibitors and Metformin as Initial 
Combination Therapy and as Monotherapy in Patients 
with Type 2 Diabetes Mellitus: a Meta-analysis. 
Diabetes, Obesity, & Metabolism. 16(1). 30-37. 
Retrieved from 
http://web.a.ebscohost.com/ehost/search/advanced?s
id=f15070a0-ed65-4645-b218-
33475188a1bd%40sessionmgr4002&vid=0&hid=4201 
McCulloch, D. K., Nathan, D. M., & Mulder, J. E. (2015). Initial 
Management Of Blood Glucose in Adults with Type 2 
Diabetes Mellitus. UpToDate.com. Retrieved from 
http://www.uptodate.com/contents/initial-
management-of-blood-glucose-in-adults-with-type-2-
diabetes-
mellitus?source=search_result&search=insulin+therap
y+in+type+2+diabetes&selectedTitle=19~150  
McCulloch, D. K., Nathan, D. M., & Mulder, J. E. (2015). 
Insulin Therapy in Type 2 Diabetes Mellitus. 
UpToDate.com. Retrieved from 
http://www.uptodate.com/contents/insulin-therapy-
in-type-2-diabetes-
mellitus?source=search_result&search=insulin+therap
y+in+type+2+diabetes&selectedTitle=1~150  
McCulloch, D. K., Nathan, D. M., & Mulder, J. E. (2015). 
Management of Persistent Hyperglycemia in Type 2 
Diabetes Mellitus. UpToDate.com. Retrieved from 
http://www.uptodate.com/contents/management-of-
persistent-hyperglycemia-in-type-2-diabetes-
mellitus?source=search_result&search=insulin+therap
y+in+type+2+diabetes&selectedTitle=3~150  
McCulloch, D. K., Nathan, D. M., Wolfsdorf, J. I., & Mulder, J. E. 
(2015). Clinical Presentation and Diagnosis of Diabetes 
Mellitus in Adults. UpToDate.com. Retrieved from 
http://www.uptodate.com/contents/clinical-
presentation-and-diagnosis-of-diabetes-mellitus-in-
adults?source=search_result&search=signs+and+symp
toms+of+type+two+diabetes&selectedTitle=1~150#H
2386084  
McCulloch, D. K., Robertson, R. P., Nathan, D. M., & Mulder, J. 
E. (2014). Pathogenesis of Type 2 Diabetes Mellitus. 
UpToDate.com. Retrieved from 
http://www.uptodate.com/contents/pathogenesis-of-
type-2-diabetes-
mellitus?source=search_result&search=pathogenesis+
of+type+2+diabetes+mellitus&selectedTitle=1~150  
Wilding, J. (2015). Managing Patients with Type 2 Diabetes 
and Obesity. The Practitioner. 259(1778). 25-28. 
Retrieved from  
http://web.b.ebscohost.com/ehost/search/basic?sid=c
f606f1a-d84d-426a-b4d9-
4059a73ebe1c%40sessionmgr115&vid=0&hid=106  
 
 
Complications 
   Distal symmetrical neuropathy is 
characterized  by dysesthesia and 
paresthesia in the lower extremities (CDC, 
1991). As the neuropathy progresses with 
poor glycemic control, varying degrees and 
pain and sensation loss occur (CDC, 1991). 
Focal neuropathy is an uncommon form 
associated a blood vessel occlusion. 
Symptoms are usually unsymmetrical in 
nature and have a sudden, acute onset 
(CDC, 1991). Autonomic neuropathy 
affects multiple body systems. The 
symptoms include: orthostatic 
hypotension, gastroparesis, constipation, 
diarrhea, fecal incontinence, bladder 
dysfunction and sexual dysfunction such 
as impotence and dyspareunia (CDC, 
1991). 
1)Lower extremity ulcers and 
amputations-they are a result of diabetic 
neuropathy and cardiovascular disease 
caused by DM2 (CDC, 1991). Due to the 
loss of sensation deformities can occur 
which lead to ulcerations (CDC, 1991). 
The ulcers are slow to heal due to the 
poor blood flow from peripheral artery 
disease (CDC, 1991). Unhealed ulcers 
become infected leading to gangrene and 
osteomyelitis (CDC, !991). These 
conditions often require amputation of 
part or all of the affect area (CDC, 1991). 
50% of the nontraumatic amputations in 
the United States are a result of diabetes 
(CDC, 1991).   
6)    Insulin- It is usually added when oral 
agents become less effective and lifestyle 
changes are no longer appropriately 
controlling blood sugar. It can be added 
as an adjunct to oral medication or used 
as primary therapy. Disadvantages for 
the use of insulin therapy include weight 
gain and hypoglycemia (McCulloch, 
Nathan, Mulder, 2015)  
A. Basal insulin- intermediate to long 
acting insulin such as NPH, NPL, 
glargine, or detemir. It is given once or 
twice a day to suppress hepatic 
glucose production in a fasting state. 
(McCulloch, Nathan, Mulder, 2015). 
i. Onset-2 hours 
ii. Peak  
a. NPH (4-12 hours) 
b. NPL (6 hours) 
c. Glargine (no peak) 
d. Detemir (3-9 hours) 
iii. Duration 
a. NPH (18-28 hours) 
b. NPL (15 hours) 
c. Glargine (20-greater than 24 
hours) 
d. Detemir (6-24 hours) 
B. Prandial dose insulin- short acting or 
rapid acting insulin such as regular, 
lispro, aspart, and glulisine given after 
meals to counteract food absorption 
(McCulloch, Nathan, Mulder, 2015). 
i. Onset 
a. Regular (30 minutes)  
b. Lispro, apart and glulisine (5-
15 minutes) 
ii. Peak 
a. Regular (2-4 hours) 
b.  Lispro, apart and glulisine 
(45-75 minutes)  
iii. Duration 
a. Regular (5-8 Hours) 
b. Lispro, apart and glulisine (2-
4) 
C. Afrezza-is a recombinant 
regular human insulin 
inhalation powder (Jia-Haur 
Hu, et al., 2014).  It is market 
as the alternative to 
injectable short acting 
insulin therapy (Jia-Haur Hu, 
et al., 2014).  
7)    Bariatric surgery-this is not a primary 
treatment for DM2 but helps treat an 
underlying cause of DM2. The 
reduction of weight is associated with 
a decrease in insulin resistance. More 
than 50% of the patients who undergo 
bariatric surgery decrease their HgA1c 
within normal limits without 
medication (Wilding, 2015) 
 
 
1) Polyuria (McCulloch, Nathan, 
Wolfsdorf, & Mulder, 2015) 
2) Polydipsia (McCulloch, et al., 2015) 
3) Elevated glycated hemoglobin A1C 
A. A1C greater than 6.1% (McCulloch, 
et al. , 2015) 
4) Increased BMI (McCulloch, et 
al.,2015) 
5) Increased fasting glucose (McCulloch, 
et al.,2015) 
6) Glycosuria (McCulloch, et al.,2015) 
7) Acute changes in vision (McCulloch, et 
al.,2015) 
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Introduction 
Type II diabetes is a result of many 
cellular processes that lead to insulin 
resistance resulting in increased blood 
glucose levels (Jia-Haur Hu, et al., 
2014). Treatments for type II diabetes 
include several different classifications 
of oral hypoglycemic medications, 
insulin injections, exercise, and a 
modified diet (Jia-Haur Hu, et al., 
2014). With the number of Americans 
being diagnosed with type II diabetes 
on the rise, a strong understanding of 
the pathophysiology of the disease and 
its treatments cannot be disregarded.  
The dysregulation of fatty acid metabolism 
and decreased glycogen synthesis can be an 
inherited defect than contributes to insulin 
resistance (McCulluch, et al., 2014). The 
process of converting proinsulin to insulin is 
shown to be impaired in the beta cells of DM2 
patients. Increased amounts of proinsulin are 
still produced in DM2 to account for 
increasing demands but are not able to be 
converted into insulin due to this beta cell 
dysfunction (McCulluch, et al., 2014). Amylin 
is secreted along with insulin in the pancreatic 
beta cells. Increased amounts of amylin 
reduce glucose uptake and inhibit insulin 
secretion (McCulluch, et al., 2014). Amylin 
concentrations are found to be extremely low 
in patients with DM2 patients   (McCulluch, et 
al., 2014). Other genetic factors for DM2 
include ethnicity and having familial history of 
DM2. African americans are up to six times 
more likely to have DM2 (McCulluch, et al., 
2014). Having a first-degree relative can make 
a patient up to ten times more susceptible to 
DM2 (McCulluch, et al., 2014). Maturity onset 
of diabetes of the young or MODY is an 
autosomal dominate form of insulin resistance 
and impaired insulin secretion from a 
mutation on chromosome 7 effecting 
glucokinase genes (McCulluch, et al., 2014). 
Inflammation markers such as C reactive 
protein, IL-6, plasminogen activator inhibitor-
1, tumor necrosis factor alpha, and white cell 
count can all be linked between obesity and 
DM2, which correlates to insulin resistance 
(McCulluch, et al., 2014). 
Pathogenesis 
1)    Metformin-is the most widely used 
oral DM2 medication on the market. It 
decreases hepatic insulin production, 
decreases reabsorption of intestinal 
glucose and decreases insulin 
resistance (McCulluch, Nathan, 
Mulder, 2014). Metformin can be used 
in conjunction with other DM2 
medications or insulin therapy. 
Combination therapy with DPP-4 has 
shown to decrease patient’s HgA1c 
more than just treatment with 
Metformin alone (Liu & Wu, 2014). 
2)    DDP-4 inhibitors-The inhibit the 
enzyme GLP-1, which decreases 
fasting plasma glucose, post prandial 
glucose, and HbA1C. The common side 
effects for this class is nausea, 
headache, renal and hepatic 
dysfunction (Eyadeh, & Jennings, 
2015) 
A. This class consists of Sitagliptin, 
Saxagliptin, Linagliptin, Alogliptin 
and Vildagliptin (Eyadeh, & 
Jennings, 2015). 
3)    SGLT inhibitors- they inhibit renal 
absorption of glucose so that in is 
dumped in the urine (Eyadeh, & 
Jennings, 2015). The SGLT inhibitors 
contribute to lower blood pressure, 
weight loss, decreased lipids and 
decreased uric acid (Eyadeh, & 
Jennings, 2015). 
A. This class consists of 
Dapagliflozin, Canagliflozin, 
Empagliflozin (Eyadeh, & 
Jennings, 2015). 
4)    GLP-1 agonists-incretion secreted 
from the intestinal mucosa, which is 
released into circulation with the 
ingestion of food (Eyadeh, & Jennings, 
2015). GLP-1 agonist mimic incretion 
thus stimulation the secretion of 
insulin (Eyadeh, & Jennings, 2015). 
Nausea is the main side effect for this 
class medication (Eyadeh, & Jennings, 
2015). 
A. This class consists of Exenatide, 
Liraglutide, Lixisenatide, and 
Albiglutide (Eyadeh, & Jennings, 
2015). 
5)    Alpha glucosidase inhibitors-slow the 
absorption of intestinal glucose 
causing a slower rise in postprandial 
blood sugars (McCulluch, Nathan, 
Mulder, 2014). However, they are 
usually poorly tolerated due to their GI 
side effects (McCulluch, Nathan, 
Mulder, 2014). 
 
 
 
   Approximately 28.9 million 
Americans have been diagnosed 
with type II diabetes (Jia-Haur Hu, 
Lin, Miller, Nguyen, & Nguyen, 
2014).  It is a disease that can cause 
or potentiate numerous 
comorbidities that negatively 
affects multiple body systems if left 
untreated (Jia-Haur Hu, et al., 
2014).  In 2012, the total estimated 
cost for treatment of type II 
diabetes in America was an 
astronomical $245 billion (Jia-Haur 
Hu, et al., 2014).   
   Type II diabetes (DM2) can result from 
genetic and environmental influences or 
both. Making it difficult to determine the 
specific cause in each patient (McCulloch, 
Robertson, Nathan, & Mulder, 2014). 
However, DM2 is characterized by 
hyperglycemia, insulin resistance, and 
relative impairment in insulin secretion 
(McCulluch, et al., 2014). Hyperglycemia 
can impair pancreatic beta cell function 
thus perpetuating the body’s insulin 
resistence leading to an even worse 
metabolic state (McCulluch, et al., 2014).  
Insulin secretion helps move glucose into 
the cell, which is mediated by glucose 
transporter 2 (GLUT-2) (McCulluch, et al., 
2014). The alteration of GLUT-2 can be 
linked to a high- fat diet in a mouse model 
decreasing insulin secretion in those mice 
(McCulluch, et al., 2014). A large majority 
of DM2 patients have shown to have 
genetic susceptibility to insulin resistance 
(McCulluch, et al., 2014).  This fact could be 
attributed to idea that insulin resistance 
becomes worse with increasing age and 
body weight (McCulluch, et al., 2014). 
Individuals with the genetic predisposition 
for DM2 so signs of increased insulin 
resistance causing hyperglycemia. In a 
cyclic manner, that hyperglycemia 
contributes to future weight gain in those 
patients (McCulluch, et al., 2014). Adipose 
tissue releases leptin, adiponectin, Tumor 
necrosis factor alpha, and resistin, which 
relate to increasing insulin resistance 
(McCulluch, et al., 2014). 
Dietary and Exercise 
Recommendations 
1) Carbohydrates-50% of a patients caloric 
intake should consist of carbohydrates; but of 
that, less that 10% should be made up of 
sugars (Bussell, 2014).  
2) Sugar-it is recommended that less than 90g 
of sugar be consumed per day. However, 
these sugars should be naturally found in food 
such as honey, fruit, and milk (Bussell, 2014). 
3) Fats-total fat intake should not exceed 70g 
per day. Mono-unsaturated fats are 
recommended such as oily fish, peanuts, 
avocado, olive oil etc. (Bussell, 2014). 
4) Fiber- 24g per day are recommended. Soluble 
fiber has been shown to reduce cholesterol 
and improve blood sugar control (Bussell, 
2014). 
5) Proteins-should make up 25% of a patients 
caloric intake. It helps increase the feeling of 
satiety allowing the patient to go longer 
periods without feeling hungry (Bussell, 2014). 
1) Diabetic Retinopathy-Diabetes is one 
of the major causes of blindness (CDC, 
1991).Chronic hyperglycemia causes 
increased capillary permeability and the 
capillaries become less functional (CDC, 
1991). Due the this fact, microaneurysms 
form, retinal capillaries close, a formation 
of fibrous tissue and new vesselsare 
created, hemorrhages and/or retinal 
detachment are all signs of diabetic 
retinopathy (CDC, 1991).  
A. Glaucoma, cataracts and macular 
edema are complications resulting 
from poorly managed DM2 
2) Diabetic Nephropathy-DM2’s effect on 
the kidney is still widely unknown (CDC, 
1991). Hyperglycemia and hypertension 
contribute to diabetic glomerulosclerosis, 
increased thickening of the glomerular 
basement membrane and mesangial 
expansion (CDC, 1991). Increased blood 
flow to the kidney from hyperglycemia 
cause an increased size and weight of the 
kidney (CDC,1991). Microalbuminuria (30 
to 300 mg/day)is usually one of the first 
notable signs of kidney disease 
(CDC,1991). 
3) Cardiovascular disease-patients with 
DM2 are 2 to 3 times more likely to have 
cardiovascular disease (CDC, 1991). 
Coronary artery disease and stroke are 
common complications as a result from 
chronic hyperglycemia.  Atherosclerosis 
contributing to these complications is 
caused from abnormal platelet function, 
hyperinsulinemia, impaired blood flow 
and coagulopathies (CDC, 1991) 
Cardiovascular disease is the leading 
cause of death for patients with DM2 
(CDC, 1991). 
4) Diabetic Neuropathy-The three types 
are distal symmetrical polyneuropathy, 
focal neuropathy, and autonomic 
neuropathy. They result from poorly 
controlled blood sugar and decreased 
blood flow to the nerves (CDC, 1991). 
Complications Cont’d 
Nursing Implications 
Education, preventative care, symptom recognition 
and appropriate treatment are imperative for 
patients at risk and/or patients with type II 
diabetes (CDC, 1991). Nurses are the front line 
when it comes helping patient manage DM2. They 
must educate patients on everything from proper 
diet and exercise to when and how to take their 
medications (CDC, 1991). Nurses must be 
knowledgeable on preventative care to help 
patients monitor and avoid the many complications 
associated with DM2 (CDC, 1991). Education on 
blood sugar management and if the prescribed 
treatment is properly controlling the patient’s 
blood sugar is largely on the nurses shoulders 
(CDC, 1991). Most importantly, nurses must 
recognize the signs and symptoms of uncontrolled 
diabetes in an undiagnosed patient (CDC, 1991). 
Weight reduction through dietary 
modification can help improve glycemic 
control by decreasing insulin resistance and 
increase insulin secretion (McCulloch, 
Nathan, & Mulder, 2015). 30-60 minutes of 
moderate intensity aerobic activity is 
recommended most days of the week 
(McCulloch, Nathan, & Mulder, 2015). 
Weight lifting should be done at least twice 
per week (McCulloch, Nathan, & Mulder, 
2015 
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